Turnstone Biologics stock plunges to 52-week low of $0.35

In a stark reflection of the challenges facing the biotech sector, Turnstone Biologics Corp. (TSBX) stock has tumbled to a 52-week low, reaching a price level of just $0.35, with the company’s market capitalization shrinking to $8.6 million. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value estimates. This latest price point underscores a precipitous decline for the company, which has seen its stock value erode by an alarming 89.07% over the past year. Investors have been grappling with a mix of industry-wide pressures and company-specific hurdles, including rapid cash burn and weak profit margins. With earnings scheduled for March 20 and analyst price targets ranging from $0.40 to $1.00, the 52-week low serves as a sobering milestone for stakeholders. While the company maintains more cash than debt and a healthy current ratio of 3.75, these fundamentals haven’t prevented the stock’s decline in the competitive landscape of biotechnology. InvestingPro subscribers can access 10+ additional insights about TSBX’s financial health and future prospects.

In other recent news, Turnstone Biologics announced the discontinuation of its TIDAL-01 clinical program, which aimed at treating solid tumors. This decision was driven by the need for substantial investment in improving the manufacturing process of its Selected TIL therapy. As a result, the company is now exploring strategic alternatives, including potential mergers, acquisitions, or asset sales, to maximize shareholder value. In response to these developments, Piper Sandler downgraded Turnstone Biologics’ stock rating from Overweight to Neutral, significantly lowering the price target from $3.75 to $0.40. The downgrade reflects the removal of projected value for TIDAL-01 and the company’s reassessed valuation based on an estimated cash balance of $11 million for the first quarter of 2025. Turnstone Biologics has also engaged a financial advisor to assist with the strategic review process and is implementing workforce reductions to conserve cash. Despite these challenges, the company plans to retain essential employees to support its strategic review efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.